Literature DB >> 6421611

Sputum sol-phase proteins and elastase activity in patients with cystic fibrosis.

A H Jackson, S L Hill, S C Afford, R A Stockley.   

Abstract

Sputum and serum samples were obtained from 38 patients with cystic fibrosis seen as out-patients at routine follow-up, or from patients admitted with acute pulmonary exacerbations of their disease. Elastolytic activity was measurable in the sputum of 13 of 16 out-patient samples and detectable in 21 of 22 patients admitted with pulmonary exacerbation. The enzyme activity was inhibited by soy bean trypsin inhibitor and alpha 1 antitrypsin, but not by ethylenediamine tetracetic acid, suggesting that it was predominantly a serine proteinase, probably leucocyte elastase. The mean sputum/serum albumin ratio was 2.53 X 10(-2) (SD +/- 2.4) for the out-patients and this was not significantly different from those of patients admitted with pulmonary exacerbation. However, those patients admitted with fever had increased sputum/serum albumin ratios (mean = 4.66 X 10(-2); SD +/- 3.19) compared with those admitted with a normal temperature (mean = 1.52 X 10(-2); SD +/- 0.41. 2p less than 0.01). The albumin ratios of the pyrexial group fell with antibiotic therapy. The sputum/serum alpha 1 antitrypsin ratios were generally greater than expected (by comparison with albumin) and evidence is presented suggesting that this is due to immunological over-estimation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6421611

Source DB:  PubMed          Journal:  Eur J Respir Dis        ISSN: 0106-4339


  15 in total

1.  Sputum sol phase proteins and elastase activity in patients with clinically stable bronchiectasis.

Authors:  P Lloberes; E Montserrat; J M Montserrat; C Picado
Journal:  Thorax       Date:  1992-02       Impact factor: 9.139

Review 2.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 3.  Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good?

Authors:  M Berger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 4.  alpha-1-Antitrypsin and the pathogenesis of emphysema.

Authors:  R A Stockley
Journal:  Lung       Date:  1987       Impact factor: 2.584

5.  Chronic bronchial sepsis and progressive lung damage.

Authors:  G M Cochrane
Journal:  Br Med J (Clin Res Ed)       Date:  1985-04-06

6.  Effect of antibiotic treatment on sputum elastase in bronchiectatic outpatients in a stable clinical state.

Authors:  R A Stockley; S L Hill; H M Morrison
Journal:  Thorax       Date:  1984-06       Impact factor: 9.139

7.  Elastolytic activity of sputum and its relation to purulence and to lung function in patients with bronchiectasis.

Authors:  R A Stockley; S L Hill; H M Morrison; C M Starkie
Journal:  Thorax       Date:  1984-06       Impact factor: 9.139

8.  Mucus glycoproteins from cystic fibrotic sputum. Macromolecular properties and structural 'architecture'.

Authors:  D J Thornton; J K Sheehan; H Lindgren; I Carlstedt
Journal:  Biochem J       Date:  1991-06-15       Impact factor: 3.857

Review 9.  New perspectives in understanding and management of the respiratory disease in cystic fibrosis.

Authors:  S Suter
Journal:  Eur J Pediatr       Date:  1994-03       Impact factor: 3.183

10.  Pseudomonas and neutrophil products modify transferrin and lactoferrin to create conditions that favor hydroxyl radical formation.

Authors:  B E Britigan; B L Edeker
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.